Mazeron J J, Lusinchi A, Marinello G, Huart J, Martin M, Calitchi E, Raynal M, le Bourgeois J P, Baillet F, Pierquin B
Int J Radiat Oncol Biol Phys. 1986 Jun;12(6):895-900. doi: 10.1016/0360-3016(86)90382-2.
From July 1971 to December 1981, 33 selected patients with T1, T2 tumors of the tonsillar region were treated according to the following protocol: 1. Telecobalt therapy to the primary site and to neck nodes to a dose of 45 Gy. 2. Brachytherapy to the primary site to a dose of 30 Gy using iridium 192. 3. Boost dose to involved neck nodes with electrons, or radical neck dissection, whether N1, N2, or N3. The actuarial disease-free survival was 76% when all patient groups were included and 80% for the N0 patients. The local control rate was 100%. Disease control in the neck was 94% overall and 100% for the N0 group. These results favor the use of this protocol for superficial, minimally infiltrating tumors less than 4 cm in diameter, without obvious extension to the base of the tongue or retromolar trigone.
1971年7月至1981年12月，按照以下方案对33例经挑选的扁桃体区T1、T2期肿瘤患者进行了治疗：1. 对原发部位和颈部淋巴结进行钴远距离治疗，剂量为45 Gy。2. 使用铱192对原发部位进行近距离治疗，剂量为30 Gy。3. 对受累颈部淋巴结采用电子线加量照射，或进行根治性颈清扫术，无论N1、N2还是N3期。纳入所有患者组时，精算无病生存率为76%，N0期患者为80%。局部控制率为100%。颈部疾病控制总体为94%，N0组为100%。这些结果支持将该方案用于直径小于4 cm、无明显向舌根或磨牙后三角区扩展的浅表、浸润性极小的肿瘤。
